Response of gait deficits to neuromuscular electrical stimulation for stroke survivors.

abstract：INTRODUCTION:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered: Numerous tested drug compounds have shown no benefits in ALS p...

journal_title：Expert review of neurotherapeutics

authors： Garbuzova-Davis S,Thomson A,Kurien C,Shytle RD,Sanberg PR

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...

journal_title：Expert review of neurotherapeutics

authors： Fernández-De-Las-Peñas C,Arendt-Nielsen L

更新日期：2017-09-01 00:00:00

abstract：:Radiation-induced gliomas represent a relatively rare but an extensively published entity in the neuro-oncologic literature. Extensive retrospective cohort data in pediatric populations after therapeutic intracranial radiation show an increased risk in glioma incidence that is both patient age- and radiation dose/volu...

journal_title：Expert review of neurotherapeutics

authors： Prasad G,Haas-Kogan DA

更新日期：2009-10-01 00:00:00

abstract：:Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...

journal_title：Expert review of neurotherapeutics

authors： Biton V

更新日期：2004-11-01 00:00:00

abstract：:Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

journal_title：Expert review of neurotherapeutics

authors： Naoi M,Maruyama W

更新日期：2009-08-01 00:00:00

abstract：INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

journal_title：Expert review of neurotherapeutics

authors： Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

更新日期：2017-08-01 00:00:00

abstract：INTRODUCTION:Gait and balance impairments are common in many neurological disorders and among the elderly, are often difficult to treat, and have a significant effect on quality of life. Areas covered: Non-invasive brain stimulation (NIBS) technologies have been recognized for their therapeutic potential in various neu...

journal_title：Expert review of neurotherapeutics

authors： Ghosh S

更新日期：2019-02-01 00:00:00

abstract：:Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...

journal_title：Expert review of neurotherapeutics

authors： Obermann M,Holle D,Katsarava Z

更新日期：2011-11-01 00:00:00

abstract：:Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

journal_title：Expert review of neurotherapeutics

authors： Dorfman BJ,Jimenez-Shahed J

更新日期：2021-01-01 00:00:00

abstract：:Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...

journal_title：Expert review of neurotherapeutics

authors： Johnston A,Smith PE

更新日期：2010-12-01 00:00:00

abstract：:Headache disorders are ubiquitous, common, disabling and to a very large extent treatable in primary care. In this review, the important headache disorders are described together with their impact on public health. Suggestions are set out for their optimal management, although many of these are necessarily based more ...

journal_title：Expert review of neurotherapeutics

authors： Steiner TJ

更新日期：2004-05-01 00:00:00

abstract：:The most successful approach for treating people with Alzheimer's disease to date has been by improving cholinergic transmission using cholinesterase inhibitors. Many of these drugs selectively inhibit acetylcholinesterase but some agents inhibit both acetylcholinesterase and butyrylcholinesterase. Recent evidence fro...

journal_title：Expert review of neurotherapeutics

authors： Tasker A,Perry EK,Ballard CG

更新日期：2005-01-01 00:00:00

abstract：:Alzheimer's disease is common, incurable and disabling. It is expected to grow dramatically in prevalence over the next 50 years. At current, the standard of care for patients with mild and moderately severe Alzheimer's disease includes the use of acetylcholinesterase inhibitors. Donepezil (Aricept) is a highly select...

journal_title：Expert review of neurotherapeutics

authors： Geldmacher DS

更新日期：2004-01-01 00:00:00

abstract：:There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

journal_title：Expert review of neurotherapeutics

authors： Michelsen JW,Meyer JM

更新日期：2007-07-01 00:00:00

abstract：:Panic disorder is one of the most common anxiety disorders and has a lifetime prevalence of 3-5%. Panic attacks can begin at any age, but commonly have their onset in early adulthood between the ages of 20 and 40 years. Naturalistic data has shown that panic disorder has a chronic and relapsing course. Panic disorder ...

journal_title：Expert review of neurotherapeutics

authors： Dannon PN,Lowengrub K,Iancu I,Kotler M

更新日期：2004-03-01 00:00:00

abstract：:Parkinson's disease (PD) is characterized clinically by rest tremor, rigidity, bradykinesia and pathologically by degeneration of nigrostriatal dopamine neurons. Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of PD. Ongoing clinical and preclinical ...

journal_title：Expert review of neurotherapeutics

authors： Ramirez-Zamora A,Molho E

更新日期：2014-01-01 00:00:00

abstract：:Glatiramer acetate (GA; Copaxone(®), Teva Pharmaceuticals Inc.), approved in the USA in 1996 and EU in 2001 as first-line treatment for relapsing-remitting multiple sclerosis, is now available in 51 countries and recently gained approval for delaying conversion to clinically definite multiple sclerosis in patients wit...

journal_title：Expert review of neurotherapeutics

authors： Johnson KP

更新日期：2012-04-01 00:00:00

abstract：:Neuropathic pain is notoriously difficult to treat; currently available pharmaceutical drugs result in moderate analgesia in approximately a third of patients. As our understanding of the biological processes involved in the establishment and maintenance of neuropathic pain increases, so does the development of novel ...

journal_title：Expert review of neurotherapeutics

authors： Goss JR,Goins WF,Glorioso JC

更新日期：2007-05-01 00:00:00

abstract：:Cognitive dysfunction (CD) affects 40-65% of multiple sclerosis (MS) patients and can have a great functional impact. It can be detected in all the disease phenotypes from the early stages of the disease and tends to progress over time. Memory, complex attention, information processing speed and executive functions ar...

journal_title：Expert review of neurotherapeutics

authors： Amato MP,Zipoli V,Portaccio E

更新日期：2008-10-01 00:00:00

abstract：:With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

journal_title：Expert review of neurotherapeutics

authors： Bergamaschi R

更新日期：2006-03-01 00:00:00

abstract：INTRODUCTION:Neuromodulation techniques play an increasing role in the treatment of primary headaches. While initially reserved for refractory cases they are now increasingly taken into consideration in earlier treatment phases and in non-refractory situations. One of the main reasons for this paradigm shift is that mo...

journal_title：Expert review of neurotherapeutics

authors： Hoffmann J,May A

更新日期：2019-03-01 00:00:00

abstract：:Central pain, which follows brain and spinal cord injury remains an ill-treated entity affecting approximately 1-2 million people worldwide. When oral drugs fail, either immediately or in the long run, the only therapeutic option is neuromodulation, via either electrical or chemical means. The whole spectrum of neurom...

journal_title：Expert review of neurotherapeutics

authors： Canavero S,Bonicalzi V

更新日期：2003-09-01 00:00:00

abstract：INTRODUCTION:Antipsychotics have long been the mainstay of treatment for agitation and psychosis in Alzheimer's disease. Despite their current use successive studies have shown that they only confer a modest benefit which must be balanced against their well-established serious side effects (extrapyramidal symptoms, str...

journal_title：Expert review of neurotherapeutics

authors： Creese B,Da Silva MV,Johar I,Ballard C

更新日期：2018-06-01 00:00:00

abstract：:Neuroblastoma is a neuroectodermal tumor of childhood with poor prognosis and low survival in patients with advanced-stage disease who respond to conventional therapies but unfortunately, often present relapse. Therefore, the search for novel therapeutic strategies is warranted and represents the objective of many inv...

journal_title：Expert review of neurotherapeutics

authors： Raffaghello L,Pistoia V

更新日期：2006-04-01 00:00:00

abstract：:Natalizumab is an α-4 integrin antagonist used for the treatment of relapsing multiple sclerosis (MS). Concerns with the drug have a risen owing to a heightened risk of progressive multifocal leukoencephalopathy, which has caused some physicians to interrupt or stop treatment altogether. The article under review evalu...

journal_title：Expert review of neurotherapeutics

authors： Schaaf SM,Pitt D,Racke MK

更新日期：2011-09-01 00:00:00

abstract：:Epilepsy is one of the most common neurologic disorders in childhood that often requires long term treatment with antiepileptic drugs. Both antiepileptic treatment and the comorbidities associated with epilepsy have a negative impact on bone health in growing children. Given the fact that vitamin D deficiency is a maj...

journal_title：Expert review of neurotherapeutics

authors： Cebeci AN,Ekici B

更新日期：2014-05-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder (ADHD) is a commonly occurring behavioral disorder among children. Community-based physicians are often the primary providers of services for children with ADHD. A set of consensus guidelines has been published by the American Academy of Pediatrics that provides best-practice d...

journal_title：Expert review of neurotherapeutics

authors： Langberg JM,Brinkman WB,Lichtenstein PK,Epstein JN

更新日期：2009-04-01 00:00:00

abstract：:Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

journal_title：Expert review of neurotherapeutics

authors： Makke Y,Abou-Khalil B

更新日期：2019-10-01 00:00:00

abstract：:Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterized by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ42) and phosphorylated tau (P-tau) proteins. One of the possibl...

journal_title：Expert review of neurotherapeutics

authors： Baranowska-Wójcik E,Szwajgier D

更新日期：2020-03-01 00:00:00

abstract：:Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...

journal_title：Expert review of neurotherapeutics

authors： Hatcher S

更新日期：2006-01-01 00:00:00